Matches in SemOpenAlex for { <https://semopenalex.org/work/W2072869730> ?p ?o ?g. }
Showing items 1 to 77 of
77
with 100 items per page.
- W2072869730 endingPage "2840" @default.
- W2072869730 startingPage "2825" @default.
- W2072869730 abstract "Prevention, improved screening, and better treatment regimens have improved cancer incidence and mortality in the last decade. Chemoradiation continues to cause high morbidity in patients undergoing treatment. DNA therapeutics have the potential to modify the genes that cause tumor progression in order to produce a response that is tumor-specific, efficacious and systemic without toxicity to normal cells. The most widely used and most experimentally advanced DNA therapeutic is the antisense oligonucleotide. These oligomers are predominantly used to inhibit mRNA expression. For cancer chemotherapy, the Bcl-2 antisense oligonucleotide is currently in phase III clinical trials. Transcription factor decoys form DNA:protein heteroduplexes and produce cellular responses at the genomic rather than transcriptional level. The use of other transcription factor decoys as oncologic reagents is now being developed. The phenomenon of RNA interference has only recently been discovered to occur in plants as a response to viral infection. Small interfering RNAs cause mRNA inhibition. siRNAs also inhibit expression of mRNA, however the intracellular cascade is quite different. siRNA could prove to be more powerful and longer lasting than antisense. Several DNA therapeutics are currently being studied. This review will focus on antisense oligonucleotides, transcription factor decoys and siRNA with an emphasis on how they can be employed as anticancer agents. Mechanism of action and design strategies will be summarized, as well as therapeutic targets and demonstrated clinical efficacy for each reagent. Keywords: antisense, sirna, rnai, decoy, oligonucleotide, cancer" @default.
- W2072869730 created "2016-06-24" @default.
- W2072869730 creator A5002351822 @default.
- W2072869730 creator A5088286120 @default.
- W2072869730 date "2005-08-01" @default.
- W2072869730 modified "2023-10-16" @default.
- W2072869730 title "Oligonucleotides as Anticancer Agents: From the Benchside to the Clinic and Beyond" @default.
- W2072869730 doi "https://doi.org/10.2174/1381612054546752" @default.
- W2072869730 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16101440" @default.
- W2072869730 hasPublicationYear "2005" @default.
- W2072869730 type Work @default.
- W2072869730 sameAs 2072869730 @default.
- W2072869730 citedByCount "39" @default.
- W2072869730 countsByYear W20728697302012 @default.
- W2072869730 countsByYear W20728697302013 @default.
- W2072869730 countsByYear W20728697302015 @default.
- W2072869730 countsByYear W20728697302016 @default.
- W2072869730 countsByYear W20728697302018 @default.
- W2072869730 crossrefType "journal-article" @default.
- W2072869730 hasAuthorship W2072869730A5002351822 @default.
- W2072869730 hasAuthorship W2072869730A5088286120 @default.
- W2072869730 hasConcept C104317684 @default.
- W2072869730 hasConcept C119056186 @default.
- W2072869730 hasConcept C129312508 @default.
- W2072869730 hasConcept C138885662 @default.
- W2072869730 hasConcept C14363569 @default.
- W2072869730 hasConcept C166703698 @default.
- W2072869730 hasConcept C170493617 @default.
- W2072869730 hasConcept C179926584 @default.
- W2072869730 hasConcept C22615655 @default.
- W2072869730 hasConcept C2779179475 @default.
- W2072869730 hasConcept C2908938912 @default.
- W2072869730 hasConcept C41895202 @default.
- W2072869730 hasConcept C502942594 @default.
- W2072869730 hasConcept C54355233 @default.
- W2072869730 hasConcept C552990157 @default.
- W2072869730 hasConcept C67705224 @default.
- W2072869730 hasConcept C86803240 @default.
- W2072869730 hasConceptScore W2072869730C104317684 @default.
- W2072869730 hasConceptScore W2072869730C119056186 @default.
- W2072869730 hasConceptScore W2072869730C129312508 @default.
- W2072869730 hasConceptScore W2072869730C138885662 @default.
- W2072869730 hasConceptScore W2072869730C14363569 @default.
- W2072869730 hasConceptScore W2072869730C166703698 @default.
- W2072869730 hasConceptScore W2072869730C170493617 @default.
- W2072869730 hasConceptScore W2072869730C179926584 @default.
- W2072869730 hasConceptScore W2072869730C22615655 @default.
- W2072869730 hasConceptScore W2072869730C2779179475 @default.
- W2072869730 hasConceptScore W2072869730C2908938912 @default.
- W2072869730 hasConceptScore W2072869730C41895202 @default.
- W2072869730 hasConceptScore W2072869730C502942594 @default.
- W2072869730 hasConceptScore W2072869730C54355233 @default.
- W2072869730 hasConceptScore W2072869730C552990157 @default.
- W2072869730 hasConceptScore W2072869730C67705224 @default.
- W2072869730 hasConceptScore W2072869730C86803240 @default.
- W2072869730 hasIssue "22" @default.
- W2072869730 hasLocation W20728697301 @default.
- W2072869730 hasLocation W20728697302 @default.
- W2072869730 hasOpenAccess W2072869730 @default.
- W2072869730 hasPrimaryLocation W20728697301 @default.
- W2072869730 hasRelatedWork W146125631 @default.
- W2072869730 hasRelatedWork W1515776315 @default.
- W2072869730 hasRelatedWork W1963518998 @default.
- W2072869730 hasRelatedWork W1986704873 @default.
- W2072869730 hasRelatedWork W2015649105 @default.
- W2072869730 hasRelatedWork W2024030923 @default.
- W2072869730 hasRelatedWork W2047147668 @default.
- W2072869730 hasRelatedWork W2130501958 @default.
- W2072869730 hasRelatedWork W2404799431 @default.
- W2072869730 hasRelatedWork W4290214833 @default.
- W2072869730 hasVolume "11" @default.
- W2072869730 isParatext "false" @default.
- W2072869730 isRetracted "false" @default.
- W2072869730 magId "2072869730" @default.
- W2072869730 workType "article" @default.